{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-040232","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.980640+00:00","generated_at":"2026-05-24T15:10:50.704038+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gyre Therapeutics reports FY2024 revenue $105.8M, issues FY2025 guidance $118-128M; Phase 3 data due Q2 2025","bullets":["FY2024 revenue $105.8M (down 6.8% YoY); net income $17.9M vs loss $85.5M in 2023 on absence of IPR&D charge.","Non-GAAP adjusted net income $16.9M (down from $25.4M); cash $51.2M at year-end.","FY2025 revenue guidance $118-128M (11-21% growth) driven by planned launches of nintedanib and avatrombopag in China.","Pivotal Phase 3 trial of F351 in CHB-associated liver fibrosis topline data expected Q2 2025; U.S. Phase 2 in MASH planned.","Appointed Ping Zhang as lead independent director; Songjiang Ma appointed Chairman of Gyre Pharmaceuticals board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-040232","json":"https://secwatch.observer/filing/0000950170-25-040232.json","markdown":"https://secwatch.observer/filing/0000950170-25-040232.md","text":"https://secwatch.observer/filing/0000950170-25-040232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/0000950170-25-040232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/gyre-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:10:50.704038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}